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Abstract Epstein-Barr virus (EBV) has been implicated
in the pathogenesis of multiple sclerosis (MS). Recent
reports proposed an increased EBV-targeted humoral
immune response in MS, which appears to be more pro-
nounced in pediatric patients. However, little is known
about the CNS-derived antibody production against EBV in
patients with MS. The objective of this study was to assess
the frequency and intensity of intrathecal antibody pro-
duction against EBV as compared to other neurotropic
viruses in pediatric and adult onset MS. In cohorts of 43
childhood, 50 adult onset MS patients, 20 children and 12
adults with other CNS disorders, paired CSF and serum
samples were studied. Frequency and intensity of intrathe-
cal antibody production against EBV as compared to mea-
sles, rubella, varicella zoster (VZV) and herpes simplex
virus (HSV) were analyzed by determination of virus-spe-
ciﬁc CSF-to-serum Antibody Indices (AI). Intrathecally
synthesized EBV antibodies were detectable in 26% pedi-
atric and 10% adult onset MS patients, compared to fre-
quencies ranging in both groups from 10 to 60% for the
other viruses. Median AIs for EBV were lower than those
for all other viruses, with more than twofold higher median
AI for measles, rubella and VZV. The EBV-targeted
humoral immune response in the CNS is only part of the
intrathecalpolyspeciﬁc antibody production inMS, directed
against various neurotropic viruses. Our results do not rule
out the possibility that EBV is involved in the pathogenesis
of MS by triggering diverse cellular immune mechanisms,
but they argue against a direct pathogenic role of EBV-
targeted humoral immune response within the CNS.
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Introduction
Epstein-Barr virus (EBV) has been implicated in the
pathogenesis of multiple sclerosis (MS) [1–19]. MS
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DOI 10.1007/s00415-009-5296-ypatients are reported to have higher EBV seropositivity
rates and serum antibody concentrations compared to
controls [4–11]. These MS-associated differences of the
humoral immune response to EBV appear to be more
pronounced in pediatric than in adult patients [8–10]. The
mechanisms by which EBV may contribute to the etiology
of MS are unknown. Recent reports proposed an increased
EBV-targeted humoral immune response in the CNS of MS
patients, but did not verify these ﬁndings in larger cohorts
with CSF-speciﬁc methods [11, 12].
An intrathecal IgG production is a key feature of both
MS and CNS infections. In neuroinfectious diseases like
herpes simplex virus (HSV) encephalitis, neuroborreliosis,
subacute sclerosing panencephalitis, varicella zoster virus
(VZV) vasculopathy and ganglionitis, at least part of the
intrathecally produced IgG is directed against the causative
agent [20–23]. This speciﬁc intrathecal immune response
is long-lasting and can be detected with high sensitivity
via calculation of the CSF-to-serum Antibody Index (AI)
[22–24].
The study of pediatric onset MS might provide better
insights into the pathogenesis of the disease than that of
adult onset MS: in comparison to adult MS patients, chil-
dren with MS have a more restricted time window between
exposure to putative environmental triggers like viral
infections and clinical expression of the disease. Immu-
nological ﬁngerprints of potentially disease-relevant
infections would therefore be expected to be more evident
in pediatric than in adult MS patients.
To study the potential role of EBV in the pathoimmu-
nology of MS, we determined the frequency and intensity
of CNS-derived antibodies against EBV versus that of
other common neurotropic viruses in childhood as com-
pared to adult onset MS patients.
Methods
A total of 125 paired serum and CSF samples (43 patients
with pediatric onset MS, 50 patients with adult onset MS,
and 32 patients with other CNS disorders) were included in
the study.
In the context of a longitudinal survey of MS patients
with a disease onset prior to age 16 years, CSF and blood
samples were obtained from children with MS at the time
of ﬁrst admission to the Department of Paediatric Neurol-
ogy, University of Go ¨ttingen, Germany, between 1997 and
2004. Diagnosis of MS was established according to the
criteria of Poser (before 2002) or McDonald (since 2002).
Paired serum and CSF samples in sufﬁcient quantity to
perform the complete assessment of virus-speciﬁc intra-
thecal antibody responses were available from 43 children.
The pediatric control group contained 20 children with
other CNS disorders, 10 of these patients had inﬂammatory
(optic neuritis: 3, neuromyelitis optica: 2, unclassiﬁed
chronic inﬂammatory CNS disease: 2, viral meningitis: 2,
concentric sclerosis Balo ´: 1), 10 noninﬂammatory CNS
diseases (headache/migraine: 2, astrocytoma: 2, seizures/
epilepsy: 2, psychosomatic disorders: 2, pseudotumor
cerebri: 1, neuroacanthocytosis: 1).
The adult onset MS group was composed of 50 con-
secutive patients undergoing lumbar puncture and diag-
nosed as MS (McDonald criteria) with a manifestation at
age 18 years or older, admitted to the Departments of
Neurology of the Universities of Go ¨ttingen and Heidelberg,
Germany, between 2004 and 2005.
The adult control group contained 12 patients with non-
inﬂammatory CNS disease (headache/migraine: 3, psychi-
atric disorders: 2, CNS metastases: 1, seizures: 1, pseudo-
tumor cerebri: 1, cognitive deterioration: 1, intracranial
hemorrhage: 1).
The study was approved by the Ethics Committee of the
Medical Faculty, Georg August University, Go ¨ttingen,
Germany.
DNA from CSF samples of 43 patients with childhood
onset MS was extracted with QIAmp DNA Blood Mini Kit
(Qiagen, Hilden, Germany), and analyzed by real-time
PCR for the presence of EBV genome (EBV LC PCR kit,
Artus, Hamburg, Germany; analytical sensitivity: 0.8
genome equivalents/lL, probit analysis p = 0.05).
Serum and CSF samples were examined for virus-spe-
ciﬁc antibodies against EBV-encoded nuclear antigen-I
(EBNA-I) and EBV-virus capsid antigen (EBV-VCA)
by ELISA kits from DRG Instruments (Dietzenbach,
Germany), and against measles, rubella, VZV and HSV by
ELISA kits from Dade Behring (Marburg, Germany).
Absorbances were measured with a microtiter plate reader
(SLT Labinstruments, Crailsheim, Germany). Calibration
curves were plotted by serial dilution of a pooled serum
(6 serial dilutions of 1:2.3). The predilution of the highest
standard concentration was chosen to obtain an optical
density of approximately 2.0, deﬁned as 100 arbitrary
concentration units. Paired CSF and serum samples were
analyzed in the same analytical run with reference to the
standard curve. Standard sample dilutions, CSF (1:15) and
serum (1:3,000), were chosen to produce absorbance values
in the linear range of the standard curve. The measured
absorbance was transferred into arbitrary concentration
units, by reference to the standard curve [24].
Albumin and IgG in CSF and serum were analyzed by
immunochemical nephelometry (Dade Behring Nephe-
lometer, Marburg, Germany). Intrathecally synthesized
virus-speciﬁc CSF antibodies were determined by calcu-
lation of the Antibody Index according to the formula:
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In the presence of a quantitatively detectable intrathecal
IgG production as identiﬁed by analysis of the CSF-to-
serum IgG versus albumin quotient diagram [22], a cor-
rected AI was calculated according to Reiber and Lange
[24]. The method-dependent, normal reference range of AI
is 0.7–1.3 (1.0 ± 2 SD). Taking into account coefﬁcients
of variation, AI values C1.5 indicate intrathecal antibody
synthesis [22, 24].
Results
CSF cells and protein content
Pleocytosis (C5 cells/lL) was noticed in 56% childhood,
62% adult onset MS, 30% pediatric and 0% adult control
patients. A total protein concentration [450 mg/L was
found in 16% childhood, 44% adult onset MS, 20% pedi-
atric and 17% adult control patients (Table 1).
EBV genome in CSF
EBV genome was not detected in any of 43 CSF samples
from childhood onset MS patients analyzed by real-time
PCR.
Intrathecal synthesis of virus-speciﬁc antibodies
An intrathecal synthesis of at least one virus-speciﬁc
antibody (measles, rubella, VZV, HSV, EBNA-I or EBV-
VCA) was detected in 31/43 (72%) childhood and 41/50
(82%) adult onset MS patients. None of 20 children and 12
adults with other CNS diseases presented intrathecally
synthesized antibodies against this selection of common
neurotropic viruses.
Frequency
Speciﬁc antibodies against EBNA-I were detected in 9 of
43 childhood and 4 of 50 adult onset MS patients, against
EBV-VCA in 6 childhood and 1 adult onset MS patients
(Table 2). Overall, 11 (26%) childhood and 5 (10%) adult
onset MS patients had evidence of an intrathecal IgG
synthesis against at least one EBV antigen. The corre-
sponding frequencies for other neurotropic viruses were
equal or higher, ranging in the childhood onset group from
26% (HSV) to 49% (VZV), in the adult onset group from
10% (HSV) to 60% (measles). All but one patient with an
intrathecal IgG production against EBV also showed an
intrathecal IgG response against at least one other virus.
Intensity
Median antibody indices (AI) for EBNA-I and EBV-VCA
were lower than those for all other viruses, with more than
twofold higher median AI for measles, rubella and VZV
(Fig. 1).
Discussion
Our study revealed that only 26% of childhood and 10% of
adult onset MS patients presented evidence for an intra-
thecal synthesis of EBV antibodies, as compared to per-
centages ranging from 30 to 60% for CNS-produced
antibodies against measles, rubella and VZV. Moreover,
median CSF speciﬁc antibody indices were not higher for
EBNA-I or EBV-VCA than for the other neurotropic
viruses, and CSF PCR results were consistently negative
for EBV.
Table 1 Characteristics of patients with MS and other CNS diseases
Multiple sclerosis Other CNS diseases
Pediatric onset (n = 43) Adult onset (n = 50) Children (n = 20) Adults (n = 12)
Gender: female/male (n) 30/13 35/15 11/9 8/4
Age at onset (years)
a 13.1/13.7 (7.9–15.9) 34.2/35.6 (18.2–54.6) 11.6/12.0 (6.9–15.7) 44.6/43.7 (20.4–70.3)
Sample acquisition age (years)
a 14.7/14.8 (10.5–17.9) 37.1/38.5 (20.2–58.6) 12.3/13.1 (7.0–16.4) 45.4/44.6 (20.4–70.8)
Sampling latency (years)
a 1.6/0.8 (0.0–6.6) 3.0/1.1 (0.0–16.2) 0.8/0.1 (0.0–7.9) 0.9/0.5 (0.0–3.9)
CSF ﬁndings
Leukocytes (cells/lL)
a 11/5 (0–75) 11/6 (0–95) 3/1 (0–15) 1/1 (0–4)
Protein (mg/L)
a 347/338 (139–961) 469/411 (146–992) 325/295 (144–644) 406/376 (203–915)
Intrathecal IgG synthesis (%)
a 29/24 (0–72) 26/25 (0–80) 2/0 (0–33) 0/0 (0–0)
Oligoclonal IgG (n)4 2 5 0 2 0
a Mean/median (range)
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123It is evident that a negative PCR for EBV in the CSF
does not exclude a prior EBV infection of the CNS in our
patients. Based on the experience with other infectious
CNS diseases, it is well known that PCR is often only
transiently positive shortly after infection, as in HSV
encephalitis. By contrast, in later disease stages, detection
of microbe-speciﬁc intrathecal antibody synthesis has been
proven a stable and sensitive diagnostic method in various
infectious CNS diseases [22, 23]. In neuroborreliosis, the
diagnostic sensitivity of the PCR is well below 40%,
whereas more than 80% of patients show intrathecally
produced antibodies against Borrelia burgdorferi [22].
Using the sensitive method of intrathecal IgG synthesis
determination, our study revealed that only a minority of
MS patients intrathecally produced IgG antibodies against
EBV. In contrast, a recent study described an increased IgG
immune response to EBV protein EBNA-I in the CSF of
MS patients as compared to controls [11]. However, this
study did not determine whether the EBNA-I antibodies in
the CSF were intrathecally produced or carried over from
blood. Thus, the reported increased CSF levels of anti-
EBNA-I IgG might have been merely the consequence of
diffusion of serum-derived antibodies into the CSF, since
elevated anti-EBNA-I serum concentrations are a known
phenomenon in MS [5–9].
The fact that intrathecally produced EBV antibodies
were absent in over 80% of our MS patients strongly
argues against a direct role for EBV in the humoral
immune response of the CNS in MS. Furthermore, median
CSF speciﬁc antibody indices (AI) were not higher for
EBNA-I or EBV-VCA than for the other common neuro-
tropic viruses analyzed. The mean AI for EBNA-I was 2,
and for EBV-VCA 4, as compared to a mean Borrelia
burgdorferi AI of 43 recently reported for patients with
neuroborreliosis [21].
In our study, CNS-produced antibodies against measles,
rubella or VZV were detectable in frequencies between 30
and 60% of pediatric and adult MS patients. All but one
patient with an intrathecal IgG production against EBV
also showed an intrathecal IgG response against at least
one of these other viruses. These ﬁndings indicate that
intrathecally produced antibodies against EBV antigens are
only part of the known polyspeciﬁc CNS antibody pro-
duction in MS, directed against diverse common neuro-
tropic viruses [21–23].
Cell mediated immune mechanisms, involving T- and
NK-cells, are of pivotal importance in controlling the
proliferation of EBV-infected B cells, and T cell cross-
recognition between EBV and myelin antigens has been
demonstrated [16, 17]. Moreover, a strong EBV-speciﬁc
CD8? T cell response in patients with early MS has been
reported recently [18]. Our results do not rule out the
possibility that EBV is involved in the pathogenesis of MS
by triggering diverse cellular immune mechanisms, but
they argue against a direct pathogenic role of EBV-targeted
humoral immune response in the CNS.
Table 2 Frequency of intrathecal antibody response (Antibody
Index C 1.5) against measles, rubella, varicella zoster, herpes sim-
plex and Epstein-Barr virus in patients with pediatric onset MS
(n = 43) and adult onset MS (n = 50)
Antibody species Intrathecal antibody synthesis
Pediatric onset
MS (%)
Adult onset
MS (%)
Measles 35 60
Rubella 30 42
Varicella zoster 49 32
Herpes simplex 26 10
Epstein-Barr virus
nuclear antigen (EBNA-I)
21 8
Epstein-Barr virus
capsid antigen (EBV-VCA)
14 2
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Fig. 1 Distribution of virus-speciﬁc CSF antibody indices (AI) of (a)
childhood onset and (b) adult onset MS patients with intrathecal
antibody synthesis (AI C 1.5) against measles, rubella, varicella
zoster (VZV), herpes simplex (HSV) or Epstein-Barr virus (EBNA-I
and EBV-VCA). Horizontal bars mark median AI values. Median AI
for EBNA-I and EBV-VCA were lower than for the other neurotropic
viruses
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